Claybrook Capital LLC acquired a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, HoldingsChannel reports. The fund acquired 2,909 shares of the medical technology company’s stock, valued at approximately $456,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Westside Investment Management Inc. raised its holdings in Stryker by 38.7% during the 4th quarter. Westside Investment Management Inc. now owns 233 shares of the medical technology company’s stock valued at $37,000 after buying an additional 65 shares during the period. DAVENPORT & Co LLC grew its position in Stryker by 1.6% in the 4th quarter. DAVENPORT & Co LLC now owns 4,340 shares of the medical technology company’s stock valued at $680,000 after acquiring an additional 70 shares during the last quarter. Wedbush Securities Inc. grew its position in Stryker by 1.6% in the 4th quarter. Wedbush Securities Inc. now owns 4,497 shares of the medical technology company’s stock valued at $705,000 after acquiring an additional 70 shares during the last quarter. Cornerstone Advisors Inc. grew its position in Stryker by 17.4% in the 3rd quarter. Cornerstone Advisors Inc. now owns 485 shares of the medical technology company’s stock valued at $86,000 after acquiring an additional 72 shares during the last quarter. Finally, BKD Wealth Advisors LLC grew its position in Stryker by 2.0% in the 4th quarter. BKD Wealth Advisors LLC now owns 3,646 shares of the medical technology company’s stock valued at $572,000 after acquiring an additional 72 shares during the last quarter. 75.46% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE SYK opened at $193.35 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.02 and a quick ratio of 1.41. The firm has a market cap of $71.49 billion, a P/E ratio of 26.45, a P/E/G ratio of 2.34 and a beta of 0.88. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $193.35.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.03. The firm had revenue of $3.80 billion during the quarter, compared to analysts’ expectations of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. As a group, equities analysts forecast that Stryker Co. will post 8.13 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date is Thursday, March 28th. Stryker’s dividend payout ratio (DPR) is currently 28.45%.
In related news, VP M Kathryn Fink sold 180 shares of the company’s stock in a transaction on Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Katherine Ann Owen sold 29,247 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $185.62, for a total value of $5,428,828.14. Following the sale, the vice president now owns 11,131 shares of the company’s stock, valued at $2,066,136.22. The disclosure for this sale can be found here. Insiders have sold a total of 74,811 shares of company stock valued at $13,409,320 over the last 90 days. 7.30% of the stock is currently owned by company insiders.
Several equities analysts have commented on the company. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Monday, November 26th. Evercore ISI raised Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 price objective on the stock in a research report on Wednesday, January 2nd. Deutsche Bank assumed coverage on Stryker in a research report on Wednesday, January 2nd. They issued a “buy” rating and a $179.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Stryker in a research report on Friday, January 18th. Finally, Barclays set a $203.00 price objective on Stryker and gave the company a “buy” rating in a research report on Friday, March 8th. Seven analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Stryker has an average rating of “Buy” and a consensus price target of $188.35.
TRADEMARK VIOLATION NOTICE: “Claybrook Capital LLC Takes $456,000 Position in Stryker Co. (SYK)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://transcriptdaily.com/2019/03/15/claybrook-capital-llc-takes-456000-position-in-stryker-co-syk.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.